From the Journals

Endometrial cancer survivors may need long-term cardiovascular monitoring


 

FROM THE JOURNAL OF THE NATIONAL CANCER INSTITUTE

Endometrial cancer survivors are at increased long-term risk for a number of adverse cardiovascular outcomes, results of a large, population-based study suggest.

Even after adjustment for potentially confounding factors, the cohort of 2,648 endometrial cancer survivors in this retrospective study had a “high burden” of cardiovascular events compared with 10,503 age-matched women, according to the investigators.

That finding highlights a need for increased monitoring and risk management for cardiovascular disease in endometrial cancer survivors, potentially for up to 10 years, according to Sean Soisson, a PhD student in the division of public health at the University of Utah, Salt Lake City, and his coinvestigators.

The study, published in the Journal of the National Cancer Institute, is not the first to find associations between endometrial cancer and long-term cardiovascular outcomes. However, many of the previous studies had small sample sizes, relied on patient-reported outcomes, or lacked a comparison group, according to investigators.

The study was based on data from the Surveillance, Epidemiology, and End Results (SEER) Utah Cancer Registry for women diagnosed between 1997 and 2012 with an invasive first primary endometrial cancer. The investigators identified cardiovascular disease diagnoses in those patients based on review of electronic medical records and ambulatory surgery and inpatient data.

Endometrial cancer survivors had elevated risks for hypertension, heart disease, and blood vessel diseases at 1-5 years after diagnosis, and for some diseases, the risk persisted at 5-10 years after diagnosis, the investigators found.

Survivors were about 50% more likely to be diagnosed with cardiac dysrhythmias compared with the general population both at 1-5 years (hazard ratio, 1.55; 99% confidence interval, 1.23-1.97) and 5-10 years (HR, 1.41; 99% CI, 1.06-1.88) after diagnosis, according to reported data.

Pages

Recommended Reading

Leg lymphedema after gynecologic lymphadenectomy exceeds expectations
MDedge Hematology and Oncology
Universal BRCA testing worthwhile for relatives of high-grade serous ovarian cancer patients
MDedge Hematology and Oncology
Bevacizumab-awwb becomes first biosimilar approved for cancer treatment
MDedge Hematology and Oncology
MDedge Daily News: How Trump’s election affected contraception
MDedge Hematology and Oncology
Cochrane report: HPV vaccine proves its worth in adolescent, young adult women
MDedge Hematology and Oncology
MDedge Daily News: Do HPV vaccines really cut cancer risk?
MDedge Hematology and Oncology
Intravenous antiemetic combination is well tolerated
MDedge Hematology and Oncology
Is adjuvant chemo warranted in stage I ovarian clear cell carcinoma?
MDedge Hematology and Oncology
Sarcoma dominance in uterine carcinosarcomas linked to decreased survival
MDedge Hematology and Oncology
Female cancer researchers receive less funding than male counterparts
MDedge Hematology and Oncology